ExodusPoint Capital Management’s Terns Pharmaceuticals TERN Stock Holding History

ExodusPoint Capital Management’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.23M	Sell	80,245 -295,428	-79%	-$12.1M	0.03%	492
2025 Q4	$15.2M	Buy	+375,673	New	+$8.68M	0.12%	151
2025 Q1	–	Sell	-10,816	Closed	-$60K	–	1977
2024 Q4	$60K	Sell	10,816 -1,637,315	-99%	-$11.1M	﹤0.01%	1421
2024 Q3	$13.7M	Buy	+1,648,131	New	+$13.6M	0.08%	187
2024 Q2	–	Sell	-54,722	Closed	-$359K	–	1976
2024 Q1	$359K	Buy	54,722 +7,182	+15%	+$46.9K	﹤0.01%	1219
2023 Q4	$309K	Buy	+47,540	New	+$251K	﹤0.01%	1173

Other funds holding TERN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

ExodusPoint Capital Management's TERN Position: Q1 2026 in Review

ExodusPoint Capital Management reduced its Terns Pharmaceuticals (TERN) stake by 79% in Q1 2026, selling an estimated $12.1M and leaving 80,245 shares worth $4.23M. The position accounts for 0.03% of the portfolio, ranked #492.

ExodusPoint Capital Management first reported a position in TERN in Q4 2023 and has held it in 6 quarters since. The position peaked at $15.2M in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

ExodusPoint Capital Management held 80,245 shares of Terns Pharmaceuticals worth $4.23M as of Q1 2026.
ExodusPoint Capital Management sold 295,428 Terns Pharmaceuticals shares in Q1 2026, an estimated $12.1M.
Terns Pharmaceuticals made up 0.03% of ExodusPoint Capital Management's portfolio in Q1 2026, its #492 holding.
ExodusPoint Capital Management first reported a position in Terns Pharmaceuticals in Q4 2023 and has held it in 6 quarters since.
ExodusPoint Capital Management's Terns Pharmaceuticals position peaked at $15.2M in Q4 2025.
317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.